Eli Lilly and Company (LLY)
After hours:
| Previous close | 908.27 |
| Open | 914.11 |
| Bid | 897.40 x 1000 |
| Ask | 901.55 x 1000 |
| Day's range | 895.00 - 915.11 |
| 52-week range | 516.57 - 972.53 |
| Volume | |
| Avg. volume | 3,243,317 |
| Market cap | 817.829B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 111.13 |
| EPS (TTM) | 8.11 |
| Earnings date | 30 Oct 2024 |
| Forward dividend & yield | 5.20 (0.58%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | 1,000.89 |
ZacksTop Stock Reports for Visa, AbbVie & Anheuser-Busch
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
PR NewswireWith once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections. The data were published in The Lancet and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.
ZacksTerns Stock Soars on Positive Data From Phase I Study of Obesity Drug
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
